SK Bioscience CEO Ahn Jae-yong holds a press conference to unveil the company's strategy SK Bioscience Co., the drug-making unit of South Korea’s SK Group, plans to spend 2.4 trillion won ($1.8 billion) over the next five years and seek mergers and acquisitions to expand its business port
AstraZeneca's Forxiga South Korea's pharmaceutical companies are competing to sell generic drugs to raise their presence on the domestic market for diabetes treatment with the expiration of the patent of AstraZeneca's Forxiga, whose active ingredient is dapagliflozin. Sales of Forxiga are an e
An SK Bioscience researcher SK Discovery Co., an intermediate holding company of South Korea’s third-largest conglomerate SK Group, will take charge of the entire biotechnology and pharmaceutical businesses at its affiliates for efficient management.According to industry officials on Thur
SK Bioscience CEO Ahn Jae-yong unveils the company's long-term business plans SK Bioscience Co., the biopharmaceutical unit of South Korea’s SK Group, is seeking multi-billion-dollar mergers and acquisitions to expand its business portfolio from contract manufacturing to gene therapy deve
SK Bioscience facility in North Gyeongsang Province SK Bioscience Co. said it reached a deal with Korea’s disease control agency to supply 10 million doses of the country’s first experimental COVID-19 vaccine.This is the first time a vaccine developed by a South Korean company has s